The FDA has reclassified radiological computer-assisted detection (CAD) and diagnosis (CADx) software from class III (highest risk) to class II (special controls).
Key Details
- 1The FDA finalized the order on June 13, moving CAD/CADx software used in radiology to class II regulation.
- 2Devices affected include software aiding detection and diagnosis on medical images like CT, MRI, and X-ray.
- 3Special controls now apply, such as design verification, validation, and clear labeling requirements.
- 4This change lowers the regulatory burden, enabling access via the 510(k) process instead of De Novo or PMA routes.
- 5Reclassification intends to maintain safety and effectiveness while enhancing patient and industry access to innovative tools.
Why It Matters
This regulatory change will significantly streamline the approval process for imaging AI developers, reducing time-to-market and promoting innovation. For radiologists, it could lead to faster clinical adoption of advanced CAD tools, with maintained safety standards.
Source
AuntMinnie
Related News
•Radiology Business
Women's Uncertainty About AI in Breast Imaging May Limit Acceptance
Many women remain unclear about the role of AI in breast imaging, creating hesitation toward its adoption.
•AuntMinnie
Stanford Team Introduces Real-Time AI Safety Monitoring for Radiology
Stanford researchers introduced an ensemble monitoring model to provide real-time confidence assessments for FDA-cleared radiology AI tools.
•Radiology Business
Harrison.ai Receives FDA Breakthrough Status for Imaging AI Device
Harrison.ai has been awarded three FDA breakthrough device designations for its imaging AI solutions, including a tool for obstructive hydrocephalus triage.